Suppr超能文献

心力衰竭的潜在生物标志物。

Potential biomarkers for heart failure.

机构信息

Department of Cardiology, Henan Provincial People's Hospital, Fuwai Central China Cardiovascular Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan, China.

出版信息

J Cell Physiol. 2019 Jun;234(6):9467-9474. doi: 10.1002/jcp.27632. Epub 2018 Oct 28.

Abstract

In this study, we identified candidate biomarkers for heart failure (HF). The gene expression profile GSE57338, containing 117 ischemic cardiomyopathic HF and 136 control samples, was downloaded and analyzed using various bioinformatics approaches. In total, 376 differentially expressed genes (DEGs) were identified, and four modules were explored in protein-protein interaction networks. DEGs (including ankyrin repeat and SOCS box-containing 14 [ASB14]) in the modules were mainly categorized by the function. Several relationships including interferon regulatory factor 1 (IRF1)-C-C motif chemokine ligand 5 (CCL5) were revealed in the transcription factor microRNA target gene regulatory network. Gene-drug analysis revealed 11 DEGs (such as the cluster of differentiation 163 [CD163]) for the target drugs. Data verification analysis identified 118 overlapping DEGs including ASB14, CD163, and CCL5. ASB14 may be involved in HF progression via protein ubiquitination and CCL5 may be involved in HF via the IRF1-CCL5 interaction. Genes including CD163 are potential biomarkers for HF.

摘要

在这项研究中,我们确定了心力衰竭(HF)的候选生物标志物。下载并使用各种生物信息学方法分析包含 117 个缺血性心肌病性 HF 和 136 个对照样本的基因表达谱 GSE57338。总共鉴定出 376 个差异表达基因(DEGs),并在蛋白质-蛋白质相互作用网络中探索了四个模块。模块中的 DEGs(包括锚蛋白重复和含 SOCS 框蛋白 14 [ASB14])主要按功能分类。转录因子 microRNA 靶基因调控网络中揭示了几种关系,包括干扰素调节因子 1(IRF1)-C-C 基序趋化因子配体 5(CCL5)。基因-药物分析显示 11 个 DEGs(如分化簇 163 [CD163])为靶药物。数据验证分析确定了包括 ASB14、CD163 和 CCL5 在内的 118 个重叠的 DEGs。ASB14 可能通过蛋白质泛素化参与 HF 进展,而 CCL5 可能通过 IRF1-CCL5 相互作用参与 HF。包括 CD163 在内的基因可能是 HF 的潜在生物标志物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验